Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B

Journal of Clinical Virology

Volumn 54, Issue 1, 2012, Pages 93-95

  Kittner, Jens M ^a   Sprinzl, Martin F ^b   Grambihler, Annette ^a   Weinmann, Arndt ^a   Schattenberg, Jörn M ^a   Galle, Peter R ^a   Schuchmann, Marcus ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

HBsAg seroconversion; Hepatitis b; Nucleos(t)ide analogues; Peg IFN add on therapy

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; TENOFOVIR; VIRUS DNA;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE EXACERBATION; FATIGUE; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; LIVER FIBROSIS; MALE; MONOTHERAPY; PARESTHESIA; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PSORIASIS; SEROCONVERSION;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84861865262     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.01.024     Document Type: Article

References (16)

1. Giacomin A., Cazzagon N., Sergio A., Vanin V., Farinati F. Hepatitis B virus-related hepatocellular carcinoma: primary, secondary, and tertiary prevention. Eur J Cancer Prev 2011, 20(5):381-388.
2. Brunetto M.R., Lok A.S. New approaches to optimize treatment responses in chronic hepatitis B. Antivir Ther 2010, 15(Suppl. 3):61-68.
3. Heathcote E.J., Marcellin P., Buti M., Gane E., De Man R.A., Krastev Z., et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011, 140(1):132-143.
4. Brunetto M.R., Moriconi F., Bonino F., Lau G.K., Farci P., Yurdaydin C., et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009, 49(4):1141-1150.
5. Wursthorn K., Lutgehetmann M., Dandri M., Volz T., Buggisch P., Zollner B., et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006, 44(3):675-684.
6. Wedemeyer H., Yurdaydin C., Dalekos G.N., Erhardt A., Cakaloglu Y., Degertekin H., et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011, 364(4):322-331.
7. Marcellin P., Avila C., Wursthorn K., Chuang W.-L., Lau G.K., Peng C.-Y., et al. Telbivudine plus peg-interferon in HBeAg-positive chronic hepatitis B-very potent antiviral efficacy but risk of peripheral neuropathy. EASL 2010 2010, Abstract #13.
8. Takkenberg R.B., Terpstra V., Zaaijer H.L., Weegink C.J., Dijkgraaf M.G.W., Jansen P.L.M., et al. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alfa-2a and adefovir. J Gastroenterol Hepatol 2011, 26(10):1527-1535.
9. Jaroszewicz J., Ho H., Markova A., Deterding K., Wursthorn K., Schulz S., et al. Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir Ther 2011, 16(6):915-924.
10. Mangano C., Squadrito G., Cacciola I., Carpentieri M., Foti G., Raimondo G. Effectiveness of add-on pegylated interferon alfa-2a therapy in a lamivudine-treated patient with chronic hepatitis B. Ann Hepatol 2011, 10(1):84-87.
11. Moucari R., Boyer N., Ripault M.P., Castelnau C., Mackiewicz V., Dauvergne A., et al. Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients. J Viral Hepat 2011, 18(August (8)):580-586.
12. Rijckborst V., Hansen B.E., Cakaloglu Y., Ferenci P., Tabak F., Akdogan M., et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010, 52(2):454-461.
13. Moucari R., Mackiewicz V., Lada O., Ripault M.P., Castelnau C., Martinot-Peignoux M., et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009, 49(4):1151-1157.
14. Sonneveld M.J., Rijckborst V., Boucher C.A.B., Hansen B.E., Janssen H.L. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010, 52(4):1251-1257.
15. Takkenberg B., de Niet A., Zaaijer H.L., Weegink C.J., Terpstra V., Dijkgraaf M., et al. Baseline HBsAg as predictor for HBsAg seroconversion in HBeAg negative chronic hepatitis B patients treated with peginterferon alfa-2a and adefovir: final results of a prospective open label study. AASLD 2011 2011, Abstract #1431.
16. Erhardt A., Blondin D., Hauck K., Sagir A., Kohnle T., Heintges T., et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005, 54(July (7)):1009-1013.